Hannah Slater

The improved survival was observed in patients treated at high-volume radiation centers with external-beam radiation therapy plus androgen-deprivation therapy.

Health literacy was associated with a reduced likelihood that a patients' screening decision would be affected by the screening-promoting effects of shared decision making.

When adjusting for only age and year of diagnosis, the mortality rate was 51% higher for Black versus White patients receiving the procedure; however, when the model adjusted for all clinical and nonclinical factors, this survival disparity dropped to 20%.

Treatment with the pan-BET bromodomain inhibitor ZEN-3694 plus enzalutamide may re-sensitize patients to androgen receptor–targeting agents.

Injection of an absorbable perirectal hydrogel spacer prior to radiotherapy for prostate cancer may reduce rectal irradiation and the associated rectal toxic effects that manifest clinically after longer-term follow-up.

A study found no association between Black race and risk of skeletal-related events and all-cause mortality in men with newly diagnosed, bone metastatic castration-resistant prostate cancer.

177Lu-PSMA-617, an investigational radioligand therapy, showed stronger clinical activity than cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.